The commercialization of silk fibroin nanofibrils based hemostatic powders
Jen-Chang Yang, Professor and Director
Expertise: Biomaterials and Medical Devices
The objective of this project is to develop a silk fibroin nanofibril based hemostatic powders. The silk fibroin (SF) was harvested from the cocoons of Bombyx mori. After oxidation and nanofibrillation, the oxidized SF nanofibrils were harvested and converted into hemostatic powders.
In the first stage, the oxidized SF nanofibril based hemostatic powders will be developed. Secondarily, an injectable sealant comprising the SF nanofibril hemostatic powders and anti-inflammation carrier will be developed as the advanced hemostats.
Benefits to industry
The global Hemostats market size is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.1% during the forecast period. Growth in this market is driven by the growing volume of surgical procedures performed, rising focus on R&D, increasing incidence of sports-related injuries and spinal ailments, and rising focus on effective blood loss management in patients during surgeries.
The photo of silk fibroin nanofibrils
Mouse Tail Bleeding Assay